REICIN ALISE 4

What Happened Reicin Alise, a director of Sana Biotechnology, received a derivative equity award on 2026-06-04 covering 90,000 shares. The filing shows a grant/award (code A) at $0.00 per share (no cash paid or exercised), so there was no immediate sale or purchase of stock.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears timely).
• Instrument: Derivative equity award (option/award) for 90,000 shares; reported price $0.00.
• Vesting: 100% vests on the earlier of (i) June 4, 2027 or (ii) immediately prior to the 2027 annual meeting, subject to continuous service (footnote F1).
• Shares owned after transaction: not specified in the supplied filing details.
• Exhibit included: Ex. 24 — Power of Attorney.

Context This was a grant of options/awards to a board member, a common form of director compensation. It is not an exercise or sale, so there was no immediate cash flow or change in free-float. The award’s future value depends on Sana’s stock performance and the vesting condition (continued service through the vest date).